Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0178874 (
tumor progression
)
40,807
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cytoplasmic polyadenylation element-binding protein 3
(
CPEB3
) is a sequence-specific RNA-binding protein. We had reported that
CPEB3
is involved in hepatocellular carcinoma (HCC) progression. However, the underlying mechanisms of
CPEB3
in HCC remain unclear. In this study, we firstly performed RNA immunoprecipitation to uncover the transcriptome-wide
CPEB3
-bound mRNAs (
CPEB3
binder) in HCC. Bioinformatic analysis indicates that
CPEB3
binders are closely related to
cancer progression
, especially HCC metastasis. Further studies confirmed that metadherin (MTDH) is a direct target of
CPEB3
.
CPEB3
can suppress the translation of MTDH mRNA in vivo and in vitro. Besides, luciferase assay demonstrated that
CPEB3
interacted with 3'-untranslated region of MTDH mRNA and inhibited its translation. Subsequently,
CPEB3
inhibited the epithelial-mesenchymal transition and metastasis of HCC cells through post-transcriptional regulation of MTDH. In addition, cpeb3 knockout mice are more susceptible to carcinogen-induced hepatocarcinogenesis and subsequent lung metastasis. Our results also indicated that
CPEB3
was a good prognosis marker, which is downregulated in HCC tissue. In conclusion, our results demonstrated that
CPEB3
played an important role in HCC progression and targeting
CPEB3
-mediated mRNA translation might be a favorable therapeutic approach.
...
PMID:CPEB3-mediated MTDH mRNA translational suppression restrains hepatocellular carcinoma progression. 3296 53